ASND — Ascendis Pharma A/S

Ownership history in Siren, L.L.C. · 6 quarters on record

This page tracks every 13F SEC filing in which Siren, L.L.C. reported a position in Ascendis Pharma A/S (ASND). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position

2.6% (2024 Q3)

Avg. % of fund

2.08%

First filed

2024 Q3

Last filed

2025 Q4

Quarters held

6

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2025 Q4	UNCHANGED	235,862	—	0%	1.50%	$50.3M	$213.24
2025 Q3	REDUCED	235,862	-10,081	-4.1%	1.83%	$46.9M	$198.81
2025 Q2	REDUCED	245,943	-41,423	-14.4%	2.20%	$42.4M	$172.60
2025 Q1	REDUCED	287,366	-9,955	-3.3%	2.55%	$44.8M	$155.86

% of Fund (quarterly) ASND price (monthly, adj. close)

Other funds also holding ASND

As of 2025 Q4 — sorted by position size

Q Global Advisors, LLC 3Y 7Y 39.86% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 22.46% Avoro Capital Advisors LLC 3Y 7Y 10.71% Resolute Capital Asset Partners LLC 3Y 9.13% Tri Locum Partners LP 3Y 7.34% WESTFIELD CAPITAL MANAGEMENT CO LP 3Y 7Y 4.61% Catalio Capital Management, LP 4.49% Spyglass Capital Management LLC 3Y 7Y 4.43% PERCEPTIVE ADVISORS LLC 3Y 7Y 4.11% PFM Health Sciences, LP 3Y 7Y 3.78%

← Back to Siren, L.L.C. Holdings